Evidence map›Paper›PMID 36899967›Full record

ArticleDiagnostics (Basel, Switzerland)2023

An m6A-Driven Prognostic Marker Panel for Renal Cell Carcinoma Based on the First Transcriptome-Wide m6A-seq.

Frank Waldbillig, Felix Bormann, Manuel Neuberger, Jörg Ellinger, Philipp Erben, Maximilian C Kriegmair, Maurice Stephan Michel, Philipp Nuhn, Malin Nientiedt

Full text read
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. NXPH4 mediated by mCellular & molecular biology letters · 2024
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Frank WaldbilligDepartment of Urology & Urosurgery, University Medical Centre Mannheim, University of Heidelberg, 68167 Mannheim, Germany.ORCID 0000-0002-6675-3799
Felix BormannBioinformatics.Expert UG, 12305 Berlin, Germany.ORCID 0000-0002-5919-3375
Manuel NeubergerDepartment of Urology & Urosurgery, University Medical Centre Mannheim, University of Heidelberg, 68167 Mannheim, Germany.ORCID 0000-0003-4573-5134
Jörg EllingerDepartment of Urology & Pediatric Urology, University Medical Centre Bonn, University of Bonn, 53127 Bonn, Germany.ORCID 0000-0002-7526-0857
Philipp ErbenDepartment of Urology & Urosurgery, University Medical Centre Mannheim, University of Heidelberg, 68167 Mannheim, Germany.ORCID 0000-0002-8279-7636
Maximilian C KriegmairDepartment of Urology & Urosurgery, University Medical Centre Mannheim, University of Heidelberg, 68167 Mannheim, Germany.
Maurice Stephan MichelDepartment of Urology & Urosurgery, University Medical Centre Mannheim, University of Heidelberg, 68167 Mannheim, Germany.
Philipp NuhnDepartment of Urology & Urosurgery, University Medical Centre Mannheim, University of Heidelberg, 68167 Mannheim, Germany.
Malin NientiedtDepartment of Urology & Urosurgery, University Medical Centre Mannheim, University of Heidelberg, 68167 Mannheim, Germany.

Funding

Medizinische Fakultät Heidelberg, Universität Heidelberg (Stiftung für Krebs- und Scharlachforschung, Mannheim) AZ 3542.2
6 · The paper itself

Abstract

To date, only a single transcriptome-wide m6A sequencing study of clear cell renal cell carcinoma (ccRCC) has been reported, with no validation so far. Herein, by TCGA analysis of the KIRC cohort (

Indexed as

epitranscriptomicskidney cancerm6A-readerMeRip-seqMETTL3N6-methyladenosine (m6A)uromodulin

Identifiers

PMID36899967
PMCPMC10001021

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read17
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.